A5076456783- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Peroxisome Proliferator-Activated Receptors
- Diabetes Treatment and Management
- Advanced Biosensing Techniques and Applications
- CAR-T cell therapy research
- Ferroptosis and cancer prognosis
- Immune cells in cancer
- Monoclonal and Polyclonal Antibodies Research
- Gallbladder and Bile Duct Disorders
- Single-cell and spatial transcriptomics
- Radiopharmaceutical Chemistry and Applications
- Cell Adhesion Molecules Research
- Biosimilars and Bioanalytical Methods
- Liver Disease Diagnosis and Treatment
- Immune Cell Function and Interaction
- Colorectal Cancer Treatments and Studies
- Cell Image Analysis Techniques
- Lung Cancer Treatments and Mutations
Johns Hopkins University
2016-2025
Sidney Kimmel Comprehensive Cancer Center
2016-2025
Johns Hopkins Medicine
2018-2025
Johns Hopkins Hospital
2016-2025
University of Baltimore
2019-2025
Bristol-Myers Squibb (Germany)
2024
AstraZeneca (France)
2024
Bloomberg (United States)
2017-2024
Convergence
2022-2024
Sidney Kimmel Cancer Center
2018-2024
Singal, Amit G.; Llovet, Josep M.; Yarchoan, Mark; Mehta, Neil; Heimbach, Julie K.; Dawson, Laura A.; Jou, Janice H.; Kulik, Agopian, Vatche Marrero, Jorge Mendiratta-Lala, Mishal; Brown, Daniel B.; Rilling, William S.; Goyal, Lipika; Wei, Alice C.; Taddei, Tamar H. Author Information
BACKGROUND. PD-L1 expression and tumor mutational burden (TMB) have emerged as important biomarkers of response to immune checkpoint inhibitor (ICI) therapy. These each succeeded failed in predicting responders for different cancer types. We sought describe the landscape across spectrum ICI-responsive human cancers, determine relationship between expression, TMB, rates ICIs.
A growing body of evidence demonstrates an association between vascular risk factors and Alzheimer's disease. This study investigated the frequency severity atherosclerotic plaques in circle Willis disease multiple other neurodegenerative diseases. Semi-quantitative data from gross microscopic neuropathological examinations 1000 cases were analysed, including 410 with a primary diagnosis disease, 230 synucleinopathies, 157 TDP-43 proteinopathies, 144 tauopathies 59 normal ageing. More than...
Immune-checkpoint therapy has failed to demonstrate meaningful clinical benefit in unselected cases of pancreatic adenocarcinoma (PDAC), but a subset PDACs are known upregulate pathways involved acquired immune suppression. Further delineation immunologic subtypes PDAC is necessary improve trial designs and identify patients who might from immune-checkpoint therapy. We used survival RNA expression data The Cancer Genome Atlas (TCGA) investigate the relationship between immune-modulating...
Immune checkpoint inhibitors provide significant clinical benefit to a subset of patients, but novel prognostic markers are needed predict which patients will respond. This study was initiated determine if features patient T cell repertoires could insights into the mechanisms immunotherapy, while also predicting outcomes.We examined receptor (TCR) in peripheral blood 25 metastatic pancreatic cancer treated with ipilimumab or without GVAX (a vaccine), as well and tumor biopsies from 32...
The relationships between absolute lymphocyte counts (ALC), drug- related toxicities, and clinical responses remain unclear in cancer patients treated with PD-1 (programmed cell death 1) inhibitors. We performed a retrospective review of 167 adult solid tumor nivolumab or pembrolizumab at single institution January 2015 November 2016. Patients an ALC >2000 baseline had increased risk irAE (OR 1.996, p<0.05) on multivariate analysis. In proportional hazards model, shorter time to progression...
To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC).
Abstract Programmed cell death protein 1 (PD-1) inhibitors have modest efficacy as a monotherapy in hepatocellular carcinoma (HCC). A personalized therapeutic cancer vaccine (PTCV) may enhance responses to PD-1 through the induction of tumor-specific immunity. We present results from single-arm, open-label, phase 1/2 study DNA plasmid PTCV (GNOS-PV02) encoding up 40 neoantigens coadministered with plasmid-encoded interleukin-12 plus pembrolizumab patients advanced HCC previously treated...
Abstract Background Novel immunotherapy combination therapies have improved outcomes for patients with hepatocellular carcinoma (HCC), but responses are limited to a subset of patients. Little is known about the inter- and intra-tumor heterogeneity in cellular signaling networks within HCC tumor microenvironment (TME) that underlie modern systemic therapy. Methods We applied spatial transcriptomics (ST) profiling characterize resection specimens from prospective clinical trial neoadjuvant...
Tumor neoantigens arising from somatic mutations in the cancer genome are less likely to be subject central immune tolerance and therefore attractive targets for vaccine immunotherapy. We utilized whole-exome sequencing, RNA sequencing (RNASeq), an silico immunogenicity prediction algorithm, NetMHC, generate a neoantigen-targeted vaccine, PancVAX, which was administered together with STING adjuvant ADU-V16 mice bearing pancreatic adenocarcinoma (Panc02) cells. PancVAX activated...
Abstract Purpose: Hepatocellular carcinoma (HCC) often arises in the setting of chronic liver inflammation and may be responsive to novel immunotherapies. Experimental Design: To characterize immune microenvironment HCC, IHC staining was performed for CD8-positive T lymphocytes, PD-1–positive, LAG-3–positive CD163-positive macrophages, PD-L1 expression tumor background from 29 cases resected HCC. Results: Expression CD8 reduced tumor, CD163 at interface. Positive clusters were identified 24...
Abstract Immuno-oncology (I-O) has required a shift in the established paradigm of toxicity and response assessment clinical research. The design interpretation cancer trials been primarily driven by conventional efficacy patterns observed with chemotherapy targeted agents, which are insufficient to fully inform trial guide therapeutic decisions I-O. Responses immune-targeted agents follow nonlinear dose–response dose–toxicity kinetics mandating development novel evaluation criteria....